JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
- Conditions
- Interventions
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 392
- Registration Number
- NCT06416410
- Locations
- 🇨🇳
Anhui Province cancer hospital, Hefei, Anhui, China
🇨🇳Pecking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Cancer Hospital Chinese Academy Of Medical Sciences, Beijing, Beijing, China
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 144
- Registration Number
- NCT06386146
- Locations
- 🇺🇸
Research site, Houston, Texas, United States
🇨🇳Research Site, Shanghai, Shanghai, China
A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 66
- Registration Number
- NCT06162169
- Locations
- 🇨🇳
Beijing GoBroad Hospital, Beijing, Beijing, China
A Study of JAB-21822 in Patients With KRAS p.G12C Mutated Pancreatic Cancer
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 69
- Registration Number
- NCT06008288
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳West China Hospital of Sichuan University, Chengdu, Sichuan, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
Mass Balance Study of [14C]JAB-21822
- First Posted Date
- 2023-06-27
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT05920941
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
A Food Effect Study of JAB-21822 in Healthy Subjects
- First Posted Date
- 2023-05-25
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT05875493
- Locations
- 🇨🇳
Beijing GoBroad Boren Hospital, Beijing, Beijing, China
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2023-01-06
- Lead Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 102
- Registration Number
- NCT05490472
- Locations
- 🇨🇳
Research site01, Changchun, Jilin, China
🇨🇳Research site02, Beijing, Beijing, China
🇺🇸University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, United States
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
- Conditions
- Interventions
- First Posted Date
- 2022-03-21
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 124
- Registration Number
- NCT05288205
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
🇨🇳Beijing Chest Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 104
- Registration Number
- NCT05276726
- Locations
- 🇨🇳
Research site05, Xiamen, Fujian, China
🇨🇳Research site08, Beijing, Beijing, China
🇨🇳Research site02, Beijing, Beijing, China
JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation
- Conditions
- Interventions
- First Posted Date
- 2022-01-18
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT05194995
- Locations
- 🇨🇳
Research site31, Beijing, Beijing, China
🇨🇳Research site01, Beijing, Beijing, China
🇨🇳Research site02, Beijing, Beijing, China